別 名
Vascular endothelial growth factor receptor 2; KDR;
VEGF Receptor 2; CD309; CD309 antigen; Fetal liver kinase 1; FLK-1; FLK1;
Kinase insert domain receptor (a type III receptor tyrosine kinase); Kinase
insert domain receptor; KRD1; Ly73; Protein tyrosine kinase receptor FLK1;
Protein-tyrosine kinase receptor flk-1; Tyrosine kinase growth factor receptor;
VEGFR 2; VEGFR; VEGFR-2; VGFR2_HUMAN.
交叉反應；Human, Mouse, Rat, (predicted: Dog, Pig, Cow, )
產品應用；ELISA=1:5000-10000
IHC-P=1:100-500 Flow-Cyt=1μg/Test （石蠟切片需做抗原修復）
not yet tested in
other applications.
optimal
dilutions/concentrations should be determined by the end user.
免 疫 原；KLH conjugated synthetic
peptide derived from human VEGFR2: 1001-1100/1356 <Cytoplasmic>
亞 型；IgG
純化方法；affinity purified by Protein A
保存條件；Shipped at 4℃. Store at -20 °C for one year. Avoid
repeated freeze/thaw cycles.
注意事項；This product as supplied is
intended for research use only, not for use in human, therapeutic or diagnostic
applications.
血管內皮生長因子受體2抗體產品介紹：
|
Tyrosine-protein
kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays
an essential role in the regulation of angiogenesis, vascular development,
vascular permeability, and embryonic hematopoiesis. Promotes proliferation,
survival, migration and differentiation of endothelial cells. Promotes
reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane
domain, such as isoform 2 and isoform 3, may function as decoy receptors for
VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative
regulator of VEGFA-and VEGFC-mediated lymphangiogenesis by limiting the
amount of fre
|